Cartesian Therapeutics (RNAC) Current Assets (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Current Assets of $122.0 million for Q1 2026, down 34.08% year-over-year from $185.1 million in Q1 2025, and down 5.6% quarter-over-quarter from $129.3 million in Q4 2025.
Cartesian Therapeutics (RNAC) Current Assets (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Current Assets for 12 consecutive years, with $122.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 34.08% year-over-year to $122.0 million; the TTM figure through Mar 2026 stood at $122.0 million (down 34.08% YoY), while the FY2025 annual figure was $129.3 million, down 40.32% from the prior year.
- Current Assets declined to $122.0 million in Q1 2026 per RNAC's latest filing, from $129.3 million in the prior quarter.
- Across five years, Current Assets topped out at $229.1 million in Q3 2024 and bottomed at $89.9 million in Q3 2023.
- Historically, Current Assets has averaged $145.9 million across 5 years, with a median of $138.4 million in 2023.
- Annual changes were most pronounced in 2023 — Current Assets sank 43.72% — and 2024, when it jumped 154.97%.
- Cartesian Therapeutics' Current Assets stood at $148.1 million in 2022, then plunged by 38.75% to $90.7 million in 2023, then surged by 138.76% to $216.6 million in 2024, then slumped by 40.32% to $129.3 million in 2025, then retreated by 5.6% to $122.0 million in 2026.
- Business Quant data shows RNAC's Current Assets at $122.0 million in Q1 2026, $129.3 million in Q4 2025, and $147.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | 153.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 153.62 Mn |
| Mar 31, 2026 | 122.04 Mn |
| Dec 31, 2025 | 129.28 Mn |
| Sep 30, 2025 | 147.26 Mn |
| Jun 30, 2025 | 163.40 Mn |
| Mar 31, 2025 | 185.12 Mn |
| Dec 31, 2024 | 216.63 Mn |
| Sep 30, 2024 | 229.14 Mn |
| Jun 30, 2024 | 124.78 Mn |
| Mar 31, 2024 | 111.11 Mn |
| Dec 31, 2023 | 90.73 Mn |
| Sep 30, 2023 | 89.87 Mn |
| Jun 30, 2023 | 122.73 Mn |
| Mar 31, 2023 | 138.39 Mn |
| Dec 31, 2022 | 148.14 Mn |
| Sep 30, 2022 | 159.68 Mn |
| Jun 30, 2022 | 172.57 Mn |
| Mar 31, 2022 | 130.01 Mn |
| Dec 31, 2021 | 144.44 Mn |
| Sep 30, 2021 | 151.77 Mn |